Wei He
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Wei He has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
Jie-Hui Zhang
Department of Neurosurgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China
1 shared publicationWei Ding
Department of Neurosurgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China
1 shared publication- Xiaojing Wang
Department of Rheumatology and Immunology, Tongren Hospital, School of Medicine Shanghai Jiao Tong University Shanghai China
1 shared publication Yu-Ran Mei
Department of Neurosurgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China
1 shared publicationZhe Zhang
Department of Neurosurgery, The Second Affiliated Hospital of Nanchang University
1 shared publicationZhen Chen
Department of Neurosurgery, The Second Affiliated Hospital of Nanchang University
1 shared publication
Latest Publications
- Open Access
- 9 May 2022
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 13, 886246
Expression and Potential Biomarkers of Regulators for M7G RNA Modification in Gliomas
Gliomas are the most frequent primary malignant brain tumors of the central nervous system, causing significant impairment and death. There is mounting evidence that N7 methylguanosine (m7G) RNA dysmethylation plays a significant role in the development and progression of cancer. However, the expression patterns and function of the m7G RNA methylation regulator in gliomas are yet unknown. The goal of this study was to examine the expression patterns of 31 critical regulators linked with m7G RNA methylation and their prognostic significance in gliomas. To begin, we systematically analyzed patient clinical and prognostic data and mRNA gene expression data from The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO) databases. We found that 17 key regulators of m7G RNA methylation showed significantly higher expression levels in gliomas. We then divided the sample into two subgroups by consensus clustering. Cluster 2 had a poorer prognosis than cluster 1 and was associated with a higher histological grade. In addition, cluster 2 was significantly enriched for cancer-related pathways. Based on this discovery, we developed a risk model involving three m7G methylation regulators. Patients were divided into high-risk and low-risk groups based on risk scores. Overall survival (OS) was significantly lower in the high-risk group than in the low-risk group. Further analysis showed that the risk score was an independent prognostic factor for gliomas.
- 9 May 2022
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 13, 886246
Open AccessExpression and Potential Biomarkers of Regulators for M7G RNA Modification in Gliomas
Gliomas are the most frequent primary malignant brain tumors of the central nervous system, causing significant impairment and death. There is mounting evidence that N7 methylguanosine (m7G) RNA dysmethylation plays a significant role in the development and progression of cancer. However, the expression patterns and function of the m7G RNA methylation regulator in gliomas are yet unknown. The goal of this study was to examine the expression patterns of 31 critical regulators linked with m7G RNA methylation and their prognostic significance in gliomas. To begin, we systematically analyzed patient clinical and prognostic data and mRNA gene expression data from The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO) databases. We found that 17 key regulators of m7G RNA methylation showed significantly higher expression levels in gliomas. We then divided the sample into two subgroups by consensus clustering. Cluster 2 had a poorer prognosis than cluster 1 and was associated with a higher histological grade. In addition, cluster 2 was significantly enriched for cancer-related pathways. Based on this discovery, we developed a risk model involving three m7G methylation regulators. Patients were divided into high-risk and low-risk groups based on risk scores. Overall survival (OS) was significantly lower in the high-risk group than in the low-risk group. Further analysis showed that the risk score was an independent prognostic factor for gliomas.